Ascentage Pharma Group International (AAPG) — SEC Filings

Overview

Ascentage Pharma Group International (AAPG) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Mar 26, 2026: ASCENTAGE PHARMA GROUP INTERNATIONAL filed a 6-K on March 26, 2026, including a press release and a Hong Kong Stock Exchange announcement, both dated March 25, 2026. This filing, with accession number 0001213900-26-034372, indicates the company is providing updated information to investors, likely r

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 6 bullish, 44 neutral. The dominant filing sentiment for Ascentage Pharma Group International is neutral.

Filing Type Overview

Ascentage Pharma Group International (AAPG) has filed 1 3, 43 6-K, 5 3/A, 1 20-F with the SEC between Feb 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (50)

• 6-K Filing — 6-K · Apr 1, 2026
• ASCENTAGE PHARMA Files 6-K with Press Release, HKEX Announce — 6-K · Mar 26, 2026
  ASCENTAGE PHARMA GROUP INTERNATIONAL filed a 6-K on March 26, 2026, including a press release and a Hong Kong Stock Exchange announcement, both dated March 25,
• ASCENTAGE PHARMA Files Amended Beneficial Ownership Statement — 3/A · Mar 23, 2026
  This 3/A filing is an amended initial statement of beneficial ownership for ASCENTAGE PHARMA GROUP INTERNATIONAL (CIK: 0002023311), filed on March 23, 2026. It
• ASCENTAGE PHARMA: Debra Yu Amends Beneficial Ownership Filing — 3/A · Mar 23, 2026
  This 3/A filing, an amendment to an initial statement of beneficial ownership, was filed on March 23, 2026, by Debra Yu, a reporting person for ASCENTAGE PHARMA
• ASCENTAGE PHARMA Amends Insider Ownership Filing for David Sidransky — 3/A · Mar 23, 2026
  This 3/A filing, an amendment to an initial statement of beneficial ownership, clarifies information related to ASCENTAGE PHARMA GROUP INTERNATIONAL (CIK: 00020
• ASCENTAGE PHARMA: Marc Lippman Ownership Filing Amended (3/A) — 3/A · Mar 23, 2026
  This 3/A filing, an amendment to an initial statement of beneficial ownership, clarifies information for ASCENTAGE PHARMA GROUP INTERNATIONAL (CIK: 0002023311).
• Knapp Joins Ascentage Pharma, Files Initial Ownership Statement — 3 · Mar 23, 2026
  This filing, a Form 3, indicates that Thomas J. Knapp has become an insider at Ascentage Pharma Group International as of March 18, 2026. A Form 3 is an initial
• ASCENTAGE PHARMA: 3/A Amends Beneficial Ownership Details — 3/A · Mar 23, 2026
  This 3/A filing, an amendment to an initial statement of beneficial ownership, clarifies details for ASCENTAGE PHARMA GROUP INTERNATIONAL (Issuer CIK: 000202331
• Ascentage Pharma Announces Board and Committee Changes — 6-K · Dec 31, 2025 Risk: low
  On December 30, 2025, Ascentage Pharma Group International announced changes to its board and committees. These include a change in the composition of the Nomin
• Ascentage Pharma to Present at J.P. Morgan Healthcare Conference — 6-K · Dec 17, 2025 Risk: low
  Ascentage Pharma Group International announced on December 17, 2025, that it will present at the 44th Annual J.P. Morgan Healthcare Conference. The company, loc
• 6-K Filing — 6-K · Dec 9, 2025
• Ascentage Pharma Presents Lisaftoclax Data at ASH Meeting — 6-K · Dec 8, 2025 Risk: low
  Ascentage Pharma Group International announced on December 6, 2025, that it presented pivotal China registrational study data for its drug Lisaftoclax at the 20
• 6-K Filing — 6-K · Dec 5, 2025
• 6-K Filing — 6-K · Dec 1, 2025
• Ascentage Pharma Grants RSUs and Share Options — 6-K · Nov 28, 2025 Risk: low
  Ascentage Pharma Group International announced on November 27, 2025, that it has made further grants of Restricted Stock Units (RSUs) under its 2022 RSU Scheme
• Ascentage Pharma GIST Drug Data Published in Nature — 6-K · Nov 25, 2025 Risk: low
  Ascentage Pharma Group International announced on November 24, 2025, that its Phase Ib study results for olverembatinib in gastrointestinal stromal tumors (GIST
• Ascentage Pharma to Attend 3 Investor Conferences in December — 6-K · Nov 19, 2025 Risk: low
  Ascentage Pharma Group International announced on November 19, 2025, that it will participate in three investor conferences in December 2025. The company, locat
• Ascentage Pharma to Present Olverembatinib Data at ASH 2025 — 6-K · Nov 4, 2025 Risk: medium
  Ascentage Pharma Group International announced on November 3, 2025, that it will present data from multiple studies of its drug Olverembatinib at the ASH 2025 c
• Ascentage Pharma to Present at Investor Conferences — 6-K · Oct 30, 2025 Risk: low
  Ascentage Pharma Group International announced on October 29, 2025, that it will participate in two investor conferences in November 2025. The company, located
• Ascentage Pharma to Attend 3 Investor Conferences in October — 6-K · Oct 7, 2025 Risk: low
  Ascentage Pharma Group International announced on October 7, 2025, that it will participate in three investor conferences during October 2025. The company, loca
• Ascentage Pharma to Attend 3 Investor Conferences in September — 6-K · Aug 28, 2025 Risk: low
  Ascentage Pharma Group International announced on August 25, 2025, that it will participate in three investor conferences in September 2025. The company, locate
• Ascentage Pharma Reports 2025 Interim Financials — 6-K · Aug 21, 2025 Risk: low
  Ascentage Pharma Group International reported its unaudited six-month financial results for the interim period ending August 20, 2025. The company, based in Suz
• Ascentage Pharma's Lisaftoclax Trial Cleared by FDA & EMA — 6-K · Aug 18, 2025 Risk: medium
  Ascentage Pharma Group International announced on August 17, 2025, that the US FDA and EMA have cleared their global registrational Phase III trial for lisaftoc
• Ascentage Pharma Announces Board Meeting — 6-K · Aug 8, 2025 Risk: low
  Ascentage Pharma Group International announced on August 8, 2025, that its Board of Directors will hold a meeting. The purpose of the meeting is not specified i
• Ascentage Pharma to Announce H1 2025 Results Aug 20 — 6-K · Aug 7, 2025 Risk: low
  Ascentage Pharma Group International announced on August 7, 2025, that they will report their 2025 six-month interim results and provide a corporate update on A
• Ascentage Pharma to Present at Evercore China Biotech Summit — 6-K · Aug 1, 2025 Risk: low
  Ascentage Pharma Group International announced on August 1, 2025, that it will participate in the Evercore China Biotech Summit. The company, headquartered in S
• Ascentage Pharma Closes Share Placing and Subscription — 6-K · Jul 25, 2025 Risk: low
  On July 25, 2025, Ascentage Pharma Group International announced the closing of a placing of existing shares and a top-up subscription of new shares under a gen
• Ascentage Pharma Closes Share Placement — 6-K · Jul 17, 2025 Risk: low
  Ascentage Pharma Group International announced the closing of its top-up placement of shares on July 17, 2025. The company, based in Suzhou, China, filed a Form
• Ascentage Pharma Enters Placing and Subscription Agreement — 6-K · Jul 15, 2025 Risk: medium
  On July 14, 2025, Ascentage Pharma Group International entered into a Placing and Subscription Agreement with The Dajun Yang Dynasty Trust, J.P. Morgan Securiti
• Ascentage Pharma's Lisaftoclax Approved in China for CLL/SLL — 6-K · Jul 10, 2025 Risk: medium
  On July 10, 2025, Ascentage Pharma Group International announced that its novel Bcl-2 inhibitor, lisaftoclax, received approval from the China National Medical
• Ascentage Pharma Names New CFO and SVP — 6-K · Jul 8, 2025 Risk: low
  Ascentage Pharma Group International announced on July 7, 2025, the appointment of Dr. Veet Misra as its new Chief Financial Officer and Eric Huang as Senior Vi
• Ascentage Pharma Grants More RSUs — 6-K · Jun 27, 2025 Risk: low
  On June 27, 2025, Ascentage Pharma Group International announced the further grant of awards under its 2021 and 2022 Restricted Stock Unit (RSU) Schemes. This a
• Ascentage Pharma Presents Olverembatinib Data at EHA 2025 — 6-K · Jun 16, 2025 Risk: medium
  On June 15, 2025, Ascentage Pharma Group International announced encouraging data from multiple studies of olverembatinib in Ph+ ALL at EHA 2025. The company al
• Ascentage Pharma Assets to be Presented at EHA Congress — 6-K · Jun 10, 2025 Risk: low
  Ascentage Pharma Group International announced on June 9, 2025, that thirteen of its drug candidates, including olverembatinib and lisafoclax, have been selecte
• Ascentage Pharma Presents Promising Alrizomadlin Data at ASCO 2025 — 6-K · Jun 3, 2025 Risk: medium
  Ascentage Pharma Group International announced promising clinical data on its drug alrizomadlin, both as a monotherapy and in combination treatments, for solid
• Ascentage Pharma's Lisaftoclax Shows Promise at ASCO 2025 — 6-K · May 23, 2025 Risk: medium
  Ascentage Pharma Group International announced on May 22, 2025, that clinical data for their drug lisaftoclax demonstrated therapeutic potential in patients who
• Ascentage Pharma Reports AGM Poll Results — 6-K · May 20, 2025 Risk: low
  Ascentage Pharma Group International filed a Form 6-K on May 20, 2025, reporting the poll results from their Annual General Meeting held on May 19, 2025. The an
• Ascentage Pharma Presents Preclinical Cancer Study Results — 6-K · Apr 28, 2025 Risk: low
  Ascentage Pharma Group International announced on April 28, 2025, that it presented results from five preclinical studies at the 2025 American Association of Ca
• Ascentage Pharma drugs in CSCO 2025 Guidelines — 6-K · Apr 21, 2025 Risk: low
  On April 21, 2025, Ascentage Pharma Group International announced that its drugs, lisafoclax and olverembatinib, have been included in the Chinese Society of Cl
• Ascentage Pharma Files 2024 Annual Report — 6-K · Apr 17, 2025 Risk: low
  Ascentage Pharma Group International filed its annual report on Form 20-F for the fiscal year ended December 31, 2024, on April 16, 2025. The company, located a
• 20-F Filing — 20-F · Apr 16, 2025
• Ascentage Pharma: Trustee Buys Shares for RSU Scheme — 6-K · Apr 8, 2025 Risk: low
  On April 8, 2025, Ascentage Pharma Group International announced a voluntary disclosure regarding the purchase of shares by the trustee for its 2022 Restricted
• Ascentage Pharma Trustee Buys Shares for RSU Scheme — 6-K · Mar 31, 2025 Risk: low
  On March 31, 2025, Ascentage Pharma Group International announced a share purchase by its trustee for the purpose of its 2022 Restricted Stock Unit (RSU) Scheme
• Ascentage Pharma Files 6-K for March 2025 — 6-K · Mar 27, 2025 Risk: low
  Ascentage Pharma Group International filed a Form 6-K on March 27, 2025, reporting information for the month of March 2025. The filing is from their principal e
• Ascentage Pharma to Present Pipeline Data at AACR 2025 — 6-K · Mar 26, 2025 Risk: low
  Ascentage Pharma Group International announced on March 25, 2025, that it will present five preclinical studies from its pipeline at the American Association of
• Ascentage Pharma Files 6-K for March 2025 — 6-K · Mar 12, 2025 Risk: low
  Ascentage Pharma Group International filed a Form 6-K on March 12, 2025. This report is for the month of March 2025 and indicates the company is a foreign priva
• Ascentage Pharma Files Routine 6-K Report — 6-K · Mar 6, 2025 Risk: low
  Ascentage Pharma Group International filed a Form 6-K on March 6, 2025, reporting for the month of March 2025. The company is a foreign private issuer based in
• Ascentage Pharma Changes Company Secretary — 6-K · Feb 25, 2025 Risk: low
  On February 25, 2025, Ascentage Pharma Group International announced a change in its Company Secretary and Authorized Representative. This update was formally c
• Ascentage Pharma Partially Exercises ADS Over-Allotment Option — 6-K · Feb 14, 2025 Risk: low
  Ascentage Pharma Group International announced the partial exercise of the over-allotment option related to its American Depositary Shares (ADS) offering on Feb
• Ascentage Pharma Partially Exercises ADS Over-Allotment Option — 6-K · Feb 11, 2025 Risk: low
  Ascentage Pharma Group International announced on February 7, 2025, the partial exercise of the over-allotment option for its American Depositary Shares (ADS) o

Related Companies

01513.HK · 002555.HK

Frequently Asked Questions